HLA-B27 Antibody (EP-4): sc-59233

HLA-B27 Antibody (EP-4) is a mouse monoclonal IgM antibody that detects HLA-B27 protein of human origin by immunofluorescence (IF). Anti-HLA-B27 antibody (EP-4) is available as a non-conjugated monoclonal isotype antibody. HLA-B27 is a member of the major histocompatibility complex (MHC) class I family, which plays a crucial role in the immune system by presenting peptide antigens to T lymphocytes, thereby initiating an immune response. HLA-B27 (EP-4) antibody is known for detecting proteins associated with various autoimmune conditions, including ankylosing spondylitis and reactive arthritis, making HLA-B27 a significant marker in clinical diagnostics. HLA-B27 is located on the surface of nearly all nucleated cells, where HLA-B27 forms a heterodimer with β-2-microglobulin, allowing presentation of endogenous peptides derived from intracellular proteins. This presentation is vital for the immune system′s ability to distinguish between self and non-self, thus preventing autoimmune reactions. The polymorphic nature of HLA-B27, with numerous alleles, contributes to varied expression in different populations and increased prevalence in certain diseases, such as uveitis. Understanding HLA-B27 function and location is essential for researchers and clinicians working to unravel the complexities of immune responses and their implications in autoimmune disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

HLA-B27 Antibody (EP-4) References:

1. The Ki-67 protein: from the known and the unknown.  |  Scholzen, T. and Gerdes, J. 2000. J Cell Physiol. 182: 311-22. PMID: 10653597
2. Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats.  |  Tran, TM., et al. 2006. Arthritis Rheum. 54: 1317-27. PMID: 16575857
3. Polymorphisms within the tumor necrosis factor-alpha promoter region in patients with HLA-B27-associated uveitis: association with susceptibility and clinical manifestations.  |  El-Shabrawi, Y., et al. 2006. Ophthalmology. 113: 695-700. PMID: 16581430
4. Anterior uveitis, inflammatory bowel disease, and ankylosing spondylitis in a HLA-B27-positive woman.  |  Singleton, EM. and Hutson, SE. 2006. South Med J. 99: 531-3. PMID: 16711320
5. Comment on 'Clinical features and outcomes of HLA B27 positive and HLA B27 negative acute anterior uveitis in a Turkish patient population'.  |  Okhravi, N. 2006. Ocul Immunol Inflamm. 14: 137-8. PMID: 16766396
6. A high-resolution polymerase chain reaction-sequence-specific primer HLA-B*27 typing set and its application in routine HLA-B27 testing.  |  Downing, J., et al. 2006. Genet Test. 10: 98-103. PMID: 16792512
7. Effective co-administration of infliximab and etanercept following the failure of sequential anti-TNF agents in a patient with HLA-B27-associated arthropathy.  |  Sheehy, C., et al. 2006. Rheumatology (Oxford). 45: 1314-5. PMID: 16837474
8. Successful treatment of juvenile-onset HLA-B27-associated severe and refractory heel thesitis with adalimumab documented by magnetic resonance imaging.  |  Olivieri, I., et al. 2006. Rheumatology (Oxford). 45: 1315-7. PMID: 16844703
9. HLA-B27-associated acute anterior uveitis in the University Referral Centre in North Thailand: clinical presentation and visual prognosis.  |  Pathanapitoon, K., et al. 2006. Br J Ophthalmol. 90: 1448-50. PMID: 16899524
10. Comparative aspects of the proliferation marker thymidine kinase 1 in human and canine tumour diseases.  |  von Euler, H. and Eriksson, S. 2011. Vet Comp Oncol. 9: 1-15. PMID: 21303450
11. Ki-67: more than a proliferation marker.  |  Sun, X. and Kaufman, PD. 2018. Chromosoma. 127: 175-186. PMID: 29322240
12. The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.  |  Zhang, A., et al. 2021. Front Endocrinol (Lausanne). 12: 687244. PMID: 34803903

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-HLA-B27 Antibody (EP-4) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-HLA-B27 Antibody (EP-4) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

HLA-B27 Antibody (EP-4) Specifications

Alternate Product Name: HLAB Serotype B27

Product Clone Name: EP-4

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgM

Amino Acids:

Epitope Target: HLA-B27

Epitope Species: human

Product Reactivity/Detection: HLA-B27

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: IF

Vialing Information: Each vial contains 100 µg IgM in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for HLA-B27 Antibody (EP-4): N/A